Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response

Sumanta K. Pal, MD, on RCC and Tumor Profiling

Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract ...

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con”...

Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture

Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the...

The

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplati...

Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immun...